Lara Goldstein

[ad_1] Lifesciences psychedelics biotech Psyence Group Inc. PSYGF recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in Southern Africa to its Contract Development & Manufacturing…

[ad_1] Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental…

[ad_1] A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12…

[ad_1] Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare IXHL announced that its Phase 2 clinical trial assessing proprietary psilocybin-assisted psychotherapy for Generalized Anxiety Disorder (GAD)…

[ad_1] Legislators in seven U.S. states are introducing psychedelics bills as they seek to emulate measures that have been approved in Oregon and Colorado.  From state-regulated psychedelic therapy programs to the legalization of…

[ad_1] Canadian clinical-stage psychedelics company Algernon Pharmaceuticals AGNPF’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed the first subject in its Phase 1 clinical study of proprietary IV formulation…

[ad_1] Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. The event is…

[ad_1] Psychedelics therapy provider Field Trip Health & Wellness Ltd. launched a new online therapy offer with the goal of providing a combination of talk therapy, integrative wellness tools and insights derived…

[ad_1] Life sciences biotech company Cybin Inc. CYBN announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its…

[ad_1] After atai Life Sciences ATAI shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psychedelics biotech’s stocks plummeted. The closing stock price…

[ad_1] Red Light Holland Moves Full Speed Towards Canadian Controlled Drugs and Substances Dealer’s License Ontario-based magic mushrooms producer Red Light Holland Corp. TRUFF hired compliance consultants Cannabis License Experts…

[ad_1] Two psychedelics companies have shared their updates and key milestones to be reached this 2023. The 5-MeO-DMT Business Clinical-stage biopharma company GH Research PLC GHRS has received initial regulatory…

[ad_1] Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. Jaguar Health…

[ad_1] Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That’s currently a measure before New York’s Senate…

[ad_1] It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year. Cybin’s Programs For…

[ad_1] Psychedelics biopharma company Reunion Neuroscience Inc. REUN announced it is undertaking a Phase 1 clinical trial on RE104, which is a novel serotonergic substance that could treat postpartum depression.  32 healthy…

[ad_1] The new non-profit, Utah Mushroom Therapy, recently launched a campaign to support the legalization of magic mushrooms, also known as psilocybin. The move follows last February’s creation of a government task force to study…

[ad_1] Clinical-stage psychedelics biotech atai Life Sciences ATAI shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression…

[ad_1] MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therapy for…

[ad_1] Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. TRYPF shared the interim results for the first five patients dosed in its Phase 2 STOP (Study of the Treatment of Overeating utilizing…

[ad_1] The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs.…

[ad_1] Psychedelics R&D biotech Biomind Labs Inc. BMNDF has completed the development of a novel sublingual formulation and the first production batch for testing in its Phase 2 trial on…

[ad_1] The Minnesota Medical Association (MMA) has recently released a resolution calling for the removal of penalties for possession of small amounts of illicit drugs as well as promoting statewide…

[ad_1] Private clinical-stage psychedelics biotech Beckley Psytech Ltd. has initiated a Phase 2a proof-of-concept study on BPL-003, its proprietary intranasal formulation of synthetic 5-MeO-DMT for Treatment-Resistant Depression (TRD.) Founded in 2019…

[ad_1] The agency regulating all things related to psychedelic-assisted therapy (PAT), Health Canada released a notice to stakeholders on risk-management measures for clinical trials, a seemingly supporting move towards future government-supported…